Moderna is considering turning its mRNA vaccine platform towards finding a vaccine to defend against Monkeypox, according to a recent tweet by the company.
There are currently two approved vaccines in the U.S. for smallpox which should be effective against Monkeypox. One is made by Acambis (since bought by Sanofi), the other made by Bavarian Nordic.
Moderna’s preclinical trials on a Monkeypox vaccine will add to its work on a host of other products, including vaccines for Covid-19, the flu, the common cold and RSV.
Underscoring this commitment, and as #monkeypox is of global public health importance as identified by the @WHO, we are investigating potential monkeypox vaccines at a preclinical level. pic.twitter.com/4VfLrxybNn
— Moderna (@moderna_tx) May 23, 2022
Moderna’s Twitter bio: